A Risk Factor For Non-small Cell Lung Cancer Patients Blood Coagulation State And Drug Intervention Of Clinical Research

BACKGROUND:In the past 20 years,the incidence of lung cancer in China’s large and medium-sized cities has increased year by year.The incidence and mortality of lung cancer in China are the top of urban malignant tumors.Non-small cell lung cancer(NSCLC)accounts for 80%of all lung cancer cases.Lung cancer surgery has a clear indication that most patients have lost the surgery when they visit.About 30 to 40 percent of the patients were found to be in the late stages and 40 percent of the patients had late metastases.The incidence of venous thromboembolism is one of the main complications of lung cancer patients,and the incidence rate is about 4-20%,and thromboembolism is the secondary cause of death in patients with malignant tumor.How to improve the survival rate and quality of life of NSCLC patients,the prevention and treatment of complications in patients with advanced NSCLC is one of the topics that clinician is worth exploring.To this end,we will common heparin in lung cancer especially in locally advanced non-small cell lung cancer palliative treatment compared with patients who were not used,to explore whether can reduce the survival rates of locally advanced non-small cell lung cancer thrombus.AIM:1、To understand the difference between healthy and NSCLC patients.2、Objective Analysis of the early warning factors of non small cell lung cancer(NSCLC)in the blood coagulation state.3、The clinical efficacy and adverse reactions of small doses of normal heparin +chemotherapy and chemotherapy alone were analyzed for the prevention and treatment of thrombotic disease in NSCLC patients.METHODS:41 cases of Healthy check-up crowd plasma coagulation indexes and platelet asnormal reference,a prospective,randomized,controlled study of the clinical data of 94 patients diagnosed as NSCLC.All of those are divided into 1he treatment group(small dose of UFH + chemotherapy)and control group(chemotherapy alone).Chemotherapy with cisplatin based combination chemotherapy.The changes of coagulation parameters,platelet,thrombosis and toxic effects were observed in the three groups.RESULTS:1)NSCLC patients with elevated plasma fibrinogen(Fib)of 50.4%,up to 7.52 g/1(normal range:2-4 g/l),D-D dimer rise up to 24.3%,up to 2.18 mg/1(normal range:0-1 mg/l).D-D dimer,Fib levels were significantly higher than that of healthy check-up crowd(P<0.05).The level of D-dimer in N.SCLC patients before and after treatment was significantly decreased(P<0.05),and the level of D-dimer in NSCLC control group was significantly increased(P<0.05).2)NSCLC treatment group before and after treatment in patients with Fib decreased obviously,and APTT significantly shortened(P<0.05),NSCLC group D-D dimer level before and after treatment significantly increased(P<0.05).NSCLC treated with small dose of ordinary UFH and processed after the comparison,Fib,D-D dimer and platelet were significantly decreased(P<0.01),APTT time significantly shortened(P<0.01).3)Treatment group in the incidence of venous thrombosis was obvious reduced incidence of venous thrombosis,there is statistical significance difference(P<0.05).CONCLUSION:1、NSCLC patients have abnormal coagulation.Plasma D-D two polymer,Fib,APTT levels can be used as a predictive risk factors for thrombosis.2、Low dose UFH can improve the high coagulation and fibrinolysis in patients with NSCLC and the application of small dose of UFH can effectively prevent the occurrence of deep vein thrombosis,and no toxic side effects of UFH.